» Articles » PMID: 25670401

Peak Experiences and the Afterglow Phenomenon: when and How Do Therapeutic Effects of Hallucinogens Depend on Psychedelic Experiences?

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2015 Feb 12
PMID 25670401
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Interest in the therapeutic potential of psychedelic substances has recently resumed. During an early phase of human psychedelic research, their therapeutic application in different pathologies had been suggested, and the first evidence for efficacy was provided. The range of recent clinical applications of psychedelics spans from cluster headaches and obsessive-compulsive disorder to addiction and the treatment of fear and anxiety in patients suffering from terminal illness, indicating potentially different therapeutic mechanisms. A variety of approaches in psychotherapy emphasize subjective experiences, such as so-called peak experiences or afterglow phenomena, as differentially mediating therapeutic action. This review aims to re-evaluate earlier and recent concepts of how psychedelic substances may exert beneficial effects. After a short outline of neurophenomenological aspects, we discuss different approaches to how psychedelics are used in psychotherapy. Finally, we summarize evidence for the relationship between subjective experiences and therapeutic success. While the distinction between pharmacological and psychological action obviously cannot be clear-cut, they do appear to contribute differently from each other when their effects are compared with regard to pathologies.

Citing Articles

A prospective ecological momentary assessment study of an ayahuasca retreat: exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life.

Sznitman S, Behar Y, Dicker-Oren S, Shochat T, Meiri D, Butto N Psychopharmacology (Berl). 2025; 242(3):545-561.

PMID: 39825910 PMC: 11861408. DOI: 10.1007/s00213-024-06704-8.


Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation.

Irrmischer M, Puxty D, Yildirim B, Deijen J, Engelbregt H Psychopharmacology (Berl). 2025; 242(4):725-740.

PMID: 39775022 PMC: 11890248. DOI: 10.1007/s00213-024-06733-3.


Neuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls.

Leistenschneider G, Majic T, Reiche S, Riemer T Sci Rep. 2024; 14(1):32159.

PMID: 39741155 PMC: 11688453. DOI: 10.1038/s41598-024-82216-x.


Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.

Koning E, Chaves C, Kirkpatrick R, Brietzke E J Eat Disord. 2024; 12(1):214.

PMID: 39731144 PMC: 11673730. DOI: 10.1186/s40337-024-01185-8.


Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.

Zahid Z, Sultan Z, Krause B, Wenthur C, Pearce R, Banks M Psychedelic Med (New Rochelle). 2024; 2(3):166-177.

PMID: 39669671 PMC: 11633440. DOI: 10.1089/psymed.2023.0061.